Clinical Trial Update: Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant sitravatinib plus nivolumab in clear cell renal cell carcinoma has completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Sitravatinib (sitravatinib)
• nivolumab (nivolumab)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Clear Cell Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2021-05-19